Maggiore Christopher D.'s Form 4/A amendment
AmendedZivo Bioscience, Inc. (ZIVO) · filed Feb 14, 2023
- Accession no.
- 0001654954-23-001647
- Filed
- Feb 14, 2023
- Trade date
- Sep 14, 2022
- Filing delay
- 153 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Sep 19, 2022
This filing lists 2 non-derivative transactions. Open-market purchases total $25.5K. It was filed 153 days after the trade.
This amendment replaces 0001654954-22-012673 (filed Sep 19, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maggiore Christopher D.CIK 0001436075 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.45 to $3.7257 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.435 to $3.93 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The total number of shares reported in Column 5 differs from amounts previously reported, which incorrectly included shares held in the estate of Robert S. McLain and in a related trust, as to which the reporting person was appointed a co-trustee in 2014. Although the reporting person has shared power to vote or to direct the vote, and shared power to dispose or to direct the disposition of, the shares held in the estate and in the trust, the reporting person has no direct or indirect pecuniary interest in such shares.